Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
artificial tears preserved with benzalkonium chloride
- Development stage
- Unknown
- Lead developer
- Mati Therapeutics
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
Artificial tears preserved with benzalkonium chloride (AT-BAK) are ophthalmic solutions evaluated by Mati Therapeutics as an adjunctive penetration enhancer for the Latanoprost Punctal Plug Delivery System (L-PPDS; Evolute). Benzalkonium chloride (BAK) is a quaternary ammonium surfactant that temporarily disrupts the tight junctions and lipid bilayer of the corneal epithelium. This disruption increases the permeability of the cornea, thereby facilitating the intraocular absorption of latanoprost released from the punctal plug into the tear film. The combination approach is intended to augment the intraocular pressure (IOP) lowering efficacy of the punctal plug system in patients with open-angle glaucoma or ocular hypertension. This strategy was investigated in a Phase 2 clinical trial to optimize drug delivery and therapeutic response.
- Other names
- Benzalkonium chloride-preserved artificial tears
Beyond the preview
Go deeper on artificial tears preserved with benzalkonium chloride.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on artificial tears preserved with benzalkonium chloride.